3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
4
Neoplasms
3
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Glioblastoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thrombosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumothorax
1
Pituitary Neoplasms
1
Philadelphia Chromosome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Opioid-Related Disorders
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metastatic Castration-resistant Prostate Cancer
1
Meningioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Ipilimumab
10
Nivolumab
9
Interleukin-2
5
Cyclophosphamide
5
pembrolizumab
3
incomplete Freund's adjuvant
3
fludarabine phosphate
3
Radiosurgery
3
Melphalan
3
ADI PEG20
3
sotrastaurin
2
fludarabine
2
Specimen Handling
2
Ranibizumab
2
Magnetic Resonance Spectroscopy
2
MART-1 Antigen
2
CTLA-4 Antigen
2
Biopsy
2
utomilumab
1
tocilizumab
1
siremadlin
1
sargramostim
1
ruxolitinib
1
relatlimab
1
pentetreotide
1
obinutuzumab
1
montanide ISA 51
1
lifileucel
1
gp100 Melanoma Antigen
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uveal Melanoma
×
Blood Specimen Collection
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled